Moss Gregory S. Buys 17,580 ANTERIS Shares as DurAVR Valve Clears French Authority, Sending Insider Confidence Surge Through the Roof

Insider Buying Fuels Optimism Amid Rapid Clinical Milestone

Anteris Technologies’ latest 4‑form filing on June 7, 2026 shows owner Moss Gregory S. purchasing 17,580 shares of the company’s common stock at roughly $9.47 per share—just above the June 7 close of $9.34. The transaction coincides with the company’s announcement that the French National Agency for Medicines and Health Products Safety has cleared its DurAVR® transcatheter heart valve for the PARADIGM trial. The buy, occurring at a price change of 0.01 % and a buzz level of 158 % on social media, suggests that insiders view the regulatory endorsement as a catalyst for near‑term share price appreciation.

What This Means for Investors

The insider purchase comes on a backdrop of strong quarterly momentum: a 45.47 % monthly gain and a 1.94 % weekly uptick. With market cap hovering near $950 million, an additional 17,580 shares—just 0.002 % of the outstanding float—may not dramatically shift the stock’s fundamentals, but it signals confidence from someone who has been accumulating restricted shares over the past year. For risk‑averse investors, the timing aligns with an upward price trajectory and a tangible clinical milestone, potentially justifying a modest premium on the current market value.

Moss Gregory S.: A Pattern of Gradual Accumulation

Gregory’s transaction history shows a consistent pattern of purchasing large blocks of restricted stock units (RSUs) rather than common shares. In December 2025 he acquired 52,742 RSUs and 13,821 RSUs, totaling 78,563 units, all of which converted to common shares on June 7, 2026. The 17,580‑share purchase represents the first outright common‑stock buy in this filing cycle. This shift from RSU conversion to a direct equity purchase may indicate a strategic move to diversify his holdings or to hedge against a potential short‑term decline in the RSU vesting schedule.

Company‑Wide Insider Activity: A Broader Context

Other insiders—such as Roberts David B and McDonnell Matthew—have also been active in June, buying and selling significant volumes of common stock and RSUs. The overall trend shows a mix of short‑term trading and longer‑term accumulation, suggesting that senior management remains optimistic yet vigilant. The recent 17,580‑share buy by Gregory aligns with this broader sentiment, reinforcing the narrative that insiders believe the company is on a solid path to commercial success.

Bottom Line

Gregory’s purchase, coupled with the regulatory clearance and a surge in social‑media buzz, positions ANTERIS Technologies for a potential breakout. While the volume of shares bought is modest relative to the float, the timing and insider confidence could signal a bullish stance that investors may wish to monitor. For those looking to capitalize on a company that is both clinically and financially ascending, the June 7 transaction is a noteworthy data point in evaluating ANTERIS’s future trajectory.